Akari Therapeutics (AKTX) Projected to Post Quarterly Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) is anticipated to post its Q4 2025 results after the market closes on Tuesday, April 7th. Analysts expect Akari Therapeutics to post earnings of ($0.0450) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 30, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Akari Therapeutics Price Performance

AKTX stock opened at $4.47 on Friday. Akari Therapeutics has a twelve month low of $4.16 and a twelve month high of $63.20. The company’s 50 day moving average is $8.54 and its two-hundred day moving average is $17.48.

Institutional Trading of Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics at the end of the most recent quarter. Institutional investors own 5.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. HC Wainwright increased their target price on shares of Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Wednesday. LADENBURG THALM/SH SH assumed coverage on shares of Akari Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Akari Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $89.00.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.